Clinical Trial

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

Study acronym: SonoPANIII
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this Interventional clinical trial is to evaluate safety and efficacy of 'IMD10 (focused ultrasound)' in the treatment of borderline resectable pancreatic cancer or locally advanced pancreatic cancer.
Protocol Amendment History 3 changes
notable Enrollment increased: 136 -> 360 participants 2026-07-16
notable Primary completion pushed: 2029-08 -> 2030-01 2026-07-16
minor Completion pushed: 2029-08 -> 2030-01 2026-07-16
Trial Details
NCT Number NCT07325214
Lead Sponsor IMGT Co., Ltd.
Conditions Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Enrollment 360 participants
Start Date 2026-09
Primary Completion 2030-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-15